Search Results for "probiotics"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for probiotics. Results 1 to 6 of 6 total matches.
Figure 1: Treatments for Irritable Bowel Syndrome (IBS) in Adults (online only)
The Medical Letter on Drugs and Therapeutics • Feb 03, 2025 (Issue 1721)
, relaxation training, or hypnotherapy
Probiotics
(optimal species, strains, dosages unknown)
Abdominal ...
View Figure: Treatments for Irritable Bowel Syndrome (IBS) in Adults
Med Lett Drugs Ther. 2025 Feb 3;67(1721):e1 doi:10.58347/tml.2025.1721c | Show Introduction Hide Introduction
Drugs for Irritable Bowel Syndrome
The Medical Letter on Drugs and Therapeutics • Feb 03, 2025 (Issue 1721)
symptoms.
Peppermint oil can decrease abdominal pain and is generally
well tolerated.
Probiotics ...
Irritable bowel syndrome (IBS) is a common disorder
characterized by recurrent abdominal pain and altered
bowel habits, often accompanied by bloating. IBS
is classified by its predominant bowel symptom:
constipation (IBS-C), diarrhea (IBS-D), mixed type
(IBS-M), or unclassified (IBS-U). Since the exact cause
of IBS is unknown, the goal of treatment is symptom
control. Some over-the-counter (OTC) products and
prescription drugs for IBS are listed in Tables 1-4. The
safety of these drugs during pregnancy and lactation
is described in Table 5 (online only).
Med Lett Drugs Ther. 2025 Feb 3;67(1721):17-24 doi:10.58347/tml.2025.1721a | Show Introduction Hide Introduction
Live Fecal Microbiota (Rebyota) for Prevention of CDI Recurrence
The Medical Letter on Drugs and Therapeutics • Mar 06, 2023 (Issue 1671)
therapy.1 Probiotics have also been
used to prevent recurrences of CDI, but data on
their efficacy ...
The FDA has approved Rebyota (Ferring), a rectally-administered,
live fecal microbiota suspension, for
prevention of additional recurrences of Clostridioides
difficile infection (CDI) following antibiotic treatment
for a recurrent episode of CDI in adults. Rebyota is
the first microbiome-based treatment to be approved
for this indication. It is not approved for initial
treatment of CDI. Fecal microbiota transplantation
(FMT) has been used in patients with multiple
CDI recurrences.
Med Lett Drugs Ther. 2023 Mar 6;65(1671):35-6 doi:10.58347/tml.2023.1671b | Show Introduction Hide Introduction
Drugs for Atopic Dermatitis
The Medical Letter on Drugs and Therapeutics • Jun 15, 2020 (Issue 1600)
with severe,
refractory AD.40
PROBIOTICS — Probiotics have been helpful in some
GI disorders41 ...
Atopic dermatitis (AD; also known as eczema) is
frequently associated with other atopic disorders
such as allergic rhinitis, asthma, and food allergy. It
commonly presents in infancy and early childhood
and has a relapsing course, often improving by
adolescence, but sometimes persisting into (or first
appearing in) adulthood or even old age.
Linaclotide (Linzess) for Functional Constipation
The Medical Letter on Drugs and Therapeutics • Aug 21, 2023 (Issue 1683)
, osmotic
and/or stimulant laxatives, stool softeners, and
probiotics are options for chronic treatment.2 ...
The guanylate cyclase-C receptor agonist linaclotide
(Linzess – Abbvie/Ironwood) was first approved by
the FDA in 2012 for treatment of chronic idiopathic
constipation and irritable bowel syndrome with
constipation in adults. The drug has now been
approved for treatment of functional constipation in
patients 6-17 years old. Linaclotide is the only drug
to be approved in the US for treatment of functional
constipation.
Med Lett Drugs Ther. 2023 Aug 21;65(1683):135-6 doi:10.58347/tml.2023.1683d | Show Introduction Hide Introduction
Treatment of Clostridioides difficile Infection
The Medical Letter on Drugs and Therapeutics • Sep 06, 2021 (Issue 1632)
in children.
Probiotics have been used to prevent recurrences of
CDI, but data on their safety and efficacy ...
Clostridioides (formerly Clostridium) difficile infection
(CDI) is the most common infectious cause of
healthcare-associated diarrhea in adults. Guidelines
on management of CDI have recently been updated.